# DESCRIPTION

## BACKGROUND OF THE DISCLOSURE

- motivate Rett syndrome research

## BRIEF SUMMARY OF THE DISCLOSURE

- disclose SEMA4D binding molecule method
- outline treatment methods for Rett syndrome

## DETAILED DESCRIPTION OF THE DISCLOSURE

### I. Definitions

- define terms for singular and plural entities
- explain use of "and/or" and "a" or "an"
- define technical and scientific terms
- specify units, prefixes, and symbols
- define "non-naturally occurring" substances
- define "neurodevelopmental disorder" and "Rett syndrome"
- define "therapeutically effective amount" and "symptoms"
- define "subject" and "binding molecule"
- explain "human" or "fully human" antibodies
- describe immunoglobulin structure and classes
- define Kabat numbering system
- describe antibody or antigen-binding fragments, variants, or derivatives
- specify heavy chain portion
- specify light chain portion
- define epitope and antigenic determinant
- describe binding affinity and avidity
- define cross-reactivity
- describe chimeric and engineered antibodies
- specify humanized antibodies
- define healthcare provider, healthcare benefits provider, and clinical laboratory

### II. Target Polypeptide Description

- define SEMA4D polypeptide
- describe structure and isoforms of SEMA4D
- summarize functional receptors and signaling pathways of SEMA4D
- discuss expression and role of SEMA4D in immune system and neurodegenerative diseases

### III. Anti-SEMA4D Antibodies

- introduce anti-SEMA4D antibodies
- describe prior art antibodies
- define method of alleviating Rett syndrome symptoms
- describe anti-SEMA4D antibody properties
- specify VH domain sequences
- specify VL domain sequences
- describe biologically active variants
- outline methods for making antibody variants
- discuss measuring binding specificity
- define percentage sequence identity

### IV. MeCP2

- describe MeCP2 protein function and its role in Rett syndrome

### V. Characteristic Symptoms of Rett Syndrome

- outline four stages of Rett syndrome

### VI. Astrocytes

- describe astrocyte function and their role in Rett syndrome
- discuss the impact of MeCP2 defects on astrocytes and Rett-like symptoms

### VII. Treatment Methods Using Therapeutic Anti-SEMA4D Antibodies

- introduce anti-SEMA4D binding molecules as a treatment for Rett syndrome
- describe the use of anti-SEMA4D antibodies to treat Rett syndrome symptoms
- outline the potential benefits of anti-SEMA4D binding molecules in Rett syndrome treatment

### VIII. Pharmaceutical Compositions and Administration Methods

- describe pharmaceutical compositions
- list administration methods
- detail parenteral administration
- describe pharmaceutical carriers
- outline preparation of injectable solutions
- discuss oral administration
- define therapeutically effective dose
- describe dosage regimens
- outline use in medicament manufacture

## EXAMPLES

### Example 1: Testing the Effects of an Anti-SEMA4D Binding Molecule on Symptoms Associated with Rett Syndrome in the Mecp2T158A Rett Syndrome Mouse Model

- design experiment
- conduct preclinical trial
- analyze behavioral tests
- evaluate anti-SEMA4D treatment effects
- compare results between pre-symptomatic and symptomatic mice
- analyze SEMA4D expression in neurons
- summarize study results

